adenine has been researched along with Retroviridae Infections in 16 studies
Retroviridae Infections: Virus diseases caused by the RETROVIRIDAE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Variables that can be experimentally manipulated to address specific questions relevant to postexposure prophylaxis (PEP) include timing of initiation of treatment, duration of treatment, dosing regimen, virus strain, and virus inoculum." | 2.40 | Animal studies of prophylaxis. ( Black, RJ, 1997) |
| "In summary, the establishment of XMRV infection in patients may be dependent on infection of A3G/A3F-deficient cells, and cells expressing low levels of A3G/A3F, such as prostate cancer cells, may be ideal producers of infectious XMRV." | 1.36 | Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs. ( Burdick, R; Chaipan, C; Delviks-Frankenberry, KA; Hu, WS; Paprotka, T; Pathak, VK; Venkatachari, NJ, 2010) |
| " Pharmacokinetic experiments in mice showed that the oral bioavailabilities of PMEA following oral gavage of Bis-PMEA or PMEA (at a dose equivalent to 28 mg of PMEA/kg) were 50." | 1.31 | Pharmacokinetic and antiretroviral activity in mice of oral [P(1),P(2)-bis[2-(adenin-9-yl)ethoxymethyl]phosphonate], a prodrug of 9-(2-phosphonylmethoxyethyl)adenine. ( Cappellacci, L; Casabianca, A; Celeste, AG; Cerasi, A; Chiarantini, L; Dominici, S; Franchetti, P; Grifantini, M; Magnani, M; Rossi, L; Serafini, S, 2002) |
| " Within < or = 2 weeks of treatment, PMPA in both dosing regimens reduced SIV levels by >99% in the plasma or peripheral blood mononuclear cells; in some macaques SIV levels were reduced to below the lower quantitation limit." | 1.30 | Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques. ( Beck, TW; Bischofberger, N; Dailey, PJ; Follis, KE; Sabo, A; Tsai, CC, 1997) |
| " Pharmacokinetic studies with mice showed that the oral bioavailability of bis(POC)-PMPA (calculated from the curves of the concentration of free PMPA in plasma) was 20%." | 1.30 | Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice. ( Annaert, P; Arimilli, MN; Augustijns, P; Bischofberger, N; De Clercq, E; Kim, CU; Naesens, L; Van den Mooter, G, 1998) |
| " Pharmacokinetic experiments with mice showed that the oral bioavailabilities of PMEA following oral gavage of bis(POM)-PMEA, diphenyl-PMEA, or PMEA (at a dose equivalent to 50 mg of PMEA per kg) were 53,3, and 16%, respectively." | 1.29 | Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine. ( Balzarini, J; Bischofberger, N; De Clercq, E; Naesens, L, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (56.25) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Paprotka, T | 1 |
| Venkatachari, NJ | 1 |
| Chaipan, C | 1 |
| Burdick, R | 1 |
| Delviks-Frankenberry, KA | 1 |
| Hu, WS | 1 |
| Pathak, VK | 1 |
| Greggs, WM | 1 |
| Clouser, CL | 1 |
| Patterson, SE | 1 |
| Mansky, LM | 1 |
| Rossi, L | 1 |
| Dominici, S | 1 |
| Serafini, S | 1 |
| Casabianca, A | 1 |
| Cerasi, A | 1 |
| Chiarantini, L | 1 |
| Celeste, AG | 1 |
| Cappellacci, L | 1 |
| Franchetti, P | 1 |
| Grifantini, M | 1 |
| Magnani, M | 1 |
| De Clercq, E | 10 |
| Balzarini, J | 5 |
| Schols, D | 1 |
| Van Laethem, K | 1 |
| Hocková, D | 1 |
| Masojidkova, M | 1 |
| Holý, A | 1 |
| Naesens, L | 3 |
| Bischofberger, N | 3 |
| Vahlenkamp, T | 1 |
| Egberink, H | 2 |
| Hartmann, K | 1 |
| Witvrouw, M | 1 |
| Pannecouque, C | 1 |
| Casara, P | 1 |
| Navé, JF | 1 |
| Tsai, CC | 1 |
| Follis, KE | 1 |
| Beck, TW | 1 |
| Sabo, A | 1 |
| Dailey, PJ | 1 |
| Augustijns, P | 1 |
| Annaert, P | 1 |
| Van den Mooter, G | 1 |
| Arimilli, MN | 1 |
| Kim, CU | 1 |
| Black, RJ | 1 |
| Hakimelahi, GH | 1 |
| Ly, TW | 1 |
| Moosavi-Movahedi, AA | 1 |
| Jain, ML | 1 |
| Zakerinia, M | 1 |
| Davari, H | 1 |
| Mei, HC | 1 |
| Sambaiah, T | 1 |
| Moshfegh, AA | 1 |
| Hakimelahi, S | 1 |
| Borst, M | 1 |
| Niphuis, H | 1 |
| Neu, H | 1 |
| Schellekens, H | 1 |
| Horzinek, M | 1 |
| Koolen, M | 1 |
6 reviews available for adenine and Retroviridae Infections
| Article | Year |
|---|---|
Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.
Topics: Adenine; Animals; Cidofovir; Cytosine; DNA Virus Infections; DNA Viruses; Humans; Organophosphonates | 2003 |
Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections.
Topics: Adenine; Animals; Antiviral Agents; Cidofovir; Cytosine; Disease Models, Animal; DNA Virus Infection | 2003 |
The potential of acyclic nucleoside phosphonates as broad-spectrum antiviral agents.
Topics: Adenine; Animals; Antiviral Agents; Cidofovir; Cytosine; Herpesviridae Infections; Humans; Organopho | 1995 |
Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections.
Topics: Adenine; Animals; Anti-HIV Agents; Antiviral Agents; Cidofovir; Cytosine; DNA Virus Infections; Huma | 1997 |
Animal studies of prophylaxis.
Topics: Adenine; Animals; Anti-HIV Agents; Disease Models, Animal; Drug Administration Schedule; Interferon- | 1997 |
Therapeutic potential of phosphonylmethoxyalkylpurines and -pyrimidines as antiviral agents.
Topics: Adenine; Animals; Antiviral Agents; Cidofovir; Cytosine; HIV Infections; Humans; Organophosphonates; | 1990 |
10 other studies available for adenine and Retroviridae Infections
| Article | Year |
|---|---|
Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs.
Topics: Adenine; Animals; Antiviral Agents; Cell Line, Tumor; Cytidine Deaminase; Gammaretrovirus; Humans; L | 2010 |
Discovery of drugs that possess activity against feline leukemia virus.
Topics: Adenine; Animals; Antiviral Agents; Azacitidine; Cat Diseases; Cats; Decitabine; Deoxycytidine; Dose | 2012 |
Pharmacokinetic and antiretroviral activity in mice of oral [P(1),P(2)-bis[2-(adenin-9-yl)ethoxymethyl]phosphonate], a prodrug of 9-(2-phosphonylmethoxyethyl)adenine.
Topics: Adenine; Administration, Oral; Animals; Antiviral Agents; Biological Availability; Blood Cell Count; | 2002 |
Pronounced in vitro and in vivo antiretroviral activity of 5-substituted 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy] pyrimidines.
Topics: Adenine; Animals; Anti-HIV Agents; Cell Line; Drug Resistance, Viral; HIV-1; HIV-2; Humans; Mice; Mo | 2007 |
Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine.
Topics: Adenine; Animals; Anti-HIV Agents; Antiviral Agents; Female; Friend murine leukemia virus; Humans; I | 1996 |
Antiretroviral activities of acyclic nucleoside phosphonates [9-(2-phosphonylmethoxyethyl)adenine, 9-(2-phosphonylmethoxyethyl)guanine, (R)-9-(2-phosphonylmethoxypropyl)adenine, and MDL 74,968] in cell cultures and murine sarcoma virus-infected newborn NM
Topics: Adenine; Animals; Animals, Newborn; Antiviral Agents; Cell Line; Fibroblasts; Guanine; Humans; Mice; | 1997 |
Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques.
Topics: Adenine; Animals; Antiviral Agents; CD4-Positive T-Lymphocytes; Drug Evaluation; Lymphocyte Count; L | 1997 |
Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice.
Topics: Adenine; Administration, Oral; Animals; Anti-HIV Agents; Biological Transport; Caco-2 Cells; Female; | 1998 |
Design, synthesis, and biological evaluation of novel nucleoside and nucleotide analogues as agents against DNA viruses and/or retroviruses.
Topics: Adenine; Adenine Nucleotides; Adenosine Deaminase Inhibitors; Animals; Antineoplastic Agents; Antivi | 2001 |
Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine.
Topics: Adenine; Animals; Antiviral Agents; Cats; Cell Line; HIV; Immunologic Deficiency Syndromes; Opportun | 1990 |